Clinical Observation Of Yangxueqingnao Granule On Blood Pressure Variability In Patients With Mild To Moderate Essential Hypertension With Deficiency Of Blood And Hyperactivity Of Liver

Objective:Observation of clinical efficacy and safety of Yangxueqingnao Granule on blood pressure variability in patients with mild to moderate essential hypertension with blood deficiency and liver dysfunction.Methods: A total of 60 patients with mild to moderate essential hypertension who were diagnosed in the Department of Cardiology of Anhui Provincial Hos pital of Traditional Chinese Medicine from January 2019 to December 2019 were patients with mild to moderate essential hypertension with blood deficiency and liver dysfunction,and were randomly divided into a western medicine control group and a Yangxueqingnao group.There were 30 cases in each group.Both groups were given lifestyle guidance and conventional antihypertensive treat ment with conventional western medicine.The Yangxueqingnao group was supplemented with Yangxueqingnao group granules(1 bag each time,3 times a day,produced by Tasly Pharmaceutical Group Co.,Ltd.,specifications.: 4g / bag,15 bags/box,batch number: Z10960082).After 8 weeks of treatment,the TCM syndrome scores and curative effects,blood pressure load curative effect,24 h ambulatory blood pressure average,24 h ambulatory blood pressure standard deviation,NO,ET-1 and other indicators and safety indicators were observed in the two groups before and after treatment.Results:1.Comparison of blood pressure efficacy:The blood pressure in the consultation room of the two groups was lower than before after treatment,(P<0.05).The blood pressure in Yangxueqingnao group decreased more significantly than in the western medicine control group(P<0.05);Yangxueqingnao group is better than the western medicine control group(P <0.05).2.Comparison of TCM syndromes:The total effective rate of the western medicine control group was 60.00%,and the total effective rate of the Yangxueqingnao group was 85.71%.The effect of the Yangxueqingnao group was better than the control group(P <0.05);TCM syndrome scores of patients in both groups decreased compared with before treatment,The effect of the Yangxueqingnao group was better than that of the control group(P <0.05);3.Comparison of mean 24 h ambulatory blood pressure:The levels of 24 h SBP,24 h DBP,DSBP,DDBP,NSBP,and NDBP in the two groups after treatment were lower than before.The effect of the Yangxueqingnao group was better than th at of the control group,and the difference was statistically significant(P <0.05);4.Comparison of 24 h ambulatory blood pressure standard deviation:The levels of24 h SSD,24 h DSD,DSSD,DDSD,NSSD,and NDSD in the two groups after treatment were lower than before treatment.The effect of the Yangxueqingnao group was better than that of the control group,and the difference was statistically significant(P <0.05);5.Comparison of NO and ET-1:NO levels of patients in both groups increased after treatment,ET-1 levels are lower than before.The effect of the Yangxueqingnao group was better than that of the control group,and the difference was statistically significant(P <0.05);6.Comparison of curative effect of blood pressure load:The total effective rate of the western medicine control group was 56.67%,and the total effective rate of the Yangxueqingnao group was 89.29%.The effect of the Yangxueqingnao group was better than that of the control group,and the difference was statistically significant(P<0.05);7.Safety comparison:There were no abnormalities in safety indicators before and after treatment in the two groups of patients,and no adverse reactions occurred.Conclusion:1.Treatment of mild-to-moderate EH patients with blood deficiency and liver dysfunction syndrome with Yangxueqingnao Granule in BPV is significantly better than control group,and Yangxueqingnao Granule can reduce TCM syndrome score,improve significantly the clinical symptoms of patients,enhance patient quality of life,have a significant clinical effect;2.Yangxueqingnao Granule can increase NO levels,down ET-1 level,have a protective effect on vascular endothelial function in patients with EH,its mechanism of action may be related to regulating vascular endothelial function;3.During the observation period,no adverse reactions occurred in the Yangxueq ingnao granule group,and no significant change in safety indicators was observed.The clinical safety is reliable.